- AVITA Medical (OTCQX:AVMXY) has achieved co -primary endpoint in its clinical trial in the treatment of third-degree burns with the RECELL Autologous Cell Harvesting Device, demonstrating a significant reduction in donor skin requirements versus standard of care while achieving comparable definitive wound closure. The results were presented at the American Burn Association 50th Annual Meeting in Chicago.
- The RECELL Device is an investigational medical device in the U.S., designed to produce, at the point-of-care, a REGENERATIVE EPIDERMAL SUSPENSION (RES) using a small sample of the patient’s own skin.
- Burn sites treated with the RECELL Device achieved definitive closure compared with standard of care. At eight weeks post treatment, 92% of the burn sites treated with RECELL achieved complete healing versus 85% for the sites treated with the standard of care, demonstrating non-inferiority. Use of RECELL was safe and well tolerated with no treatment-related adverse events considered device related.
- Now read: Why Geron Doesn't Pass Our Screens
Original article